The FDA has granted Breakthrough Designation to ElectroCore Inc's ECOR gammaCore nVNS device for posttraumatic stress disorder (PTSD).
- The device showed a reduction of symptoms of PTSD by 31% when compared to sham.
- Related: ElectroCore's Non-invasive Nerve Stimulator Effective Against Migraine.
- GammaCore (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as adjunctive therapy to treat migraine and cluster headache by utilizing a mild electrical stimulation to the vagus nerve passes through the skin.
- Price Action: ECOR shares are up 20.4% at $0.65 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in